ROCKVILLE, Md. and SEOUL, South Korea, July 15,
2024 /PRNewswire/ -- HanAll Biopharma (KRX:
009420.KS) announced today the appointment of Christopher W. Slavinsky as Chief Business
Development and Legal Officer.
"Chris brings a wealth of expertise to HanAll with his proven
track record at leading biopharmaceutical companies and deep
knowledge in legal and business strategy. His experience in driving
transformative initiatives and navigating complex regulatory
landscapes will be instrumental as we continue to innovate and
expand our presence in the industry," said Sean Jeong, M.D., MBA, CEO of HanAll
Biopharma.
Chris is expected to leverage his extensive background as a
strategic and operationally focused leader with over 25 years of
expertise in legal and business development roles within large
pharmaceutical companies and small, emerging biotechnology firms.
Spanning annual revenues from $50
million to $50 billion, he has
overseen more than $20 billion in
strategic transactions, including transformative M&A,
integration efforts, asset acquisitions, and divestitures aimed at
driving growth, ensuring regulatory compliance, and optimizing the
company's market position across R&D, commercial operations,
and investor relations functions.
Chris joins HanAll from Coherus BioSciences, where he served as
Chief Business and Legal Officer and led its $65M all-stock acquisition of Surface Oncology
and a groundbreaking biosimilars partnership with Cost Plus Drugs.
Previously, Chris held leadership positions at Pharmacosmos
Therapeutics, Prometheus Biosciences, Takeda, and Pfizer.
"I am excited to join HanAll and contribute my expertise to
pioneer cutting-edge therapies targeting unmet medical needs. I am
honored to join a talented global team and look forward to
collaborating with academic and industry partners in service of
patients in need."
Chris holds a JD from Washington
University in St. Louis, an
MS in Biochemistry and Molecular Biology from Thomas Jefferson University and a BS in
Biochemistry from the State University of New
York at Stony Brook.
About HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical
company with presence in Korea, the USA, Japan,
and Indonesia with the mission of
making meaningful contributions to patients' lives by introducing
innovative, impactful medicines to address severe unmet medical
needs. HanAll has been operating a portfolio of pharmaceutical
products in the therapeutic areas of endocrine, circulatory, and
urologic diseases for over 50 years.
HanAll has also expanded its focus to immunology, oncology,
neurology, and ophthalmology to discover and develop innovative
medicines for patients with diseases for which there are no
effective treatments. One of its lead pipeline assets, HL161 (INN:
batoclimab), an anti-FcRn antibody, is being developed in Phase 3
and Phase 2 trials across the world for the treatment of autoimmune
diseases including generalized myasthenia gravis (gMG), thyroid eye
disease (TED), chronic inflammatory demyelinating polyneuropathy
(CIDP), and Graves' disease (GD). HL161ANS (IMVT-1402), an
anti-FcRn antibody targeting multiple indications, is being
evaluated in a Phase clinical study (healthy volunteers). Another
lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is
being evaluated in Phase 3 clinical studies in the US and is also
being evaluated in China for the
treatment of dry eye disease. HL192 (ATH-399A), a Nurr1 activator
targeting Parkinson's Disease, has completed a Phase 1 study in
healthy volunteers.
For further information, visit our website and connect with
us on LinkedIn. For any media inquiries, please contact HanAll
PR/IR (pr@hanall.com, ir@hanall.com).
Disclaimer Statement
The contents of this announcement include statements that
are, or may be deemed to be, "forward-looking statements." These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms "believes,"
"estimates," "anticipates," "expects," "intends," "may," "will," or
"should," and include statements HANALL (the company, we) makes
concerning its 2024 business and financial outlook and related
plans; the therapeutic potential of its product candidates; the
intended results of its strategy and the company, and its
collaboration partners', advancement of, and anticipated clinical
development, data readouts and regulatory milestones and plans,
including the timing of planned clinical trials and expected data
readouts; the design of future clinical trials and the timing and
outcome of regulatory filings and regulatory approvals. By their
nature, forward-looking statements involve risks and uncertainties,
and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. The company's actual
results may differ materially from those predicted by the
forward-looking statements. These may include various significant
factors, such as our expectations regarding the inherent
uncertainties associated with competitive developments, preclinical
and clinical trial and product development activities, and
regulatory approval requirements. In addition, performance may be
affected by our reliance on collaborations with third parties,
estimating the commercial potential of our product candidates, our
ability to obtain and maintain protection of intellectual property
of technologies and drugs, our limited operating history, and our
ability to obtain additional funding for operations and to complete
the development and commercialization of product candidates. A
further list and description of these risks, uncertainties, and
other risks can be found in Korea Stock Exchange (KRX) filings and
reports, including in our most recent annual report as well as
subsequent filings and reports filed by the company with the KRX.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. We undertake no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by Korean law
and regulations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hanall-biopharma-appoints-christopher-w-slavinsky-as-chief-business-development-and-legal-officer-302196473.html
SOURCE HanAll Biopharma